1. In Vivo
  2. >>Deal-Making

Device/Diagnostics Quarterly Dealmaking Statistics, Q4 2018

A look at the financing, M&A and alliance activity in October–December 2018

 
• By Amanda Micklus and Maureen Riordan

Device fundraising in the fourth quarter totaled $1.5bn, a 42% decrease from Q3's $2.6bn. Q4 M&A activity reached $8.6bn. Q4 diagnostics financings brought in $1.2bn (a 32% increase over Q3) and M&As totaled $1.3bn (the second-highest quarter of the year).

In the final quarter of 2018, device fundraising reached $1.5bn, 42% down from the $2.6bn raised in Q3, and an all-time low for the year. Still in all, device financing totaled $15bn for 2018, nearly double the $8.4bn aggregate from 2017. Siemens Healthineers AG (a spin-off of Siemens AG) outlier $5.2bn IPO [See Deal] in March propelled the IPO category to $5.9bn in 2018; excluding that transaction, the total across all financing types decreases to $9.8bn for the year, but still remains an increase over 2017 (see Exhibit 1).

In Q4, late-stage venture financings and FOPOs again were the top fundraising vehicles, together bringing in just over 50% of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Deals Shaping The Industry, May 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By Ashley Yeo

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Deals In Depth: April 2025

 
• By Deanna Kamienski and Maureen Riordan

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.